What is the recommended diagnostic workup and management for interstitial fibrosis?

Diagnostic Workup and Management for Interstitial Fibrosis

The diagnosis of interstitial fibrosis requires multidisciplinary discussion integrating high-resolution computed tomography (HRCT), clinical assessment, and—when imaging is not definitive—surgical lung biopsy or transbronchial lung cryobiopsy, with management centered on antifibrotic therapy for idiopathic pulmonary fibrosis (IPF) and close monitoring for disease progression. 1

Diagnostic Workup

Initial Clinical Assessment

The diagnostic process must first exclude known causes of lung fibrosis including:

• Drug toxicity
• Collagen vascular disease
• Environmental exposures (hypersensitivity pneumonitis)
• Familial disease 1, 2

Key clinical features to document:

• Age (IPF typically affects older adults)
• Severity of dyspnea
• Smoking history
• Occupational exposures 1

High-Resolution Computed Tomography (HRCT)

HRCT is the cornerstone of diagnosis and can establish IPF without biopsy when showing a typical usual interstitial pneumonia (UIP) pattern. 1

Typical UIP pattern (diagnostic for IPF):

• Subpleural and basal predominant reticulation
• Honeycombing with traction bronchiectasis
• Absence of features suggesting alternative diagnosis 1

Possible UIP pattern (requires biopsy for definitive diagnosis):

• Subpleural and basal reticulation with traction bronchiectasis
• No honeycombing
• No features suggesting alternative diagnosis 1

Patterns inconsistent with UIP:

• Prominent diffuse ground-glass attenuation
• Mosaic attenuation pattern
• Predominant airway-centered changes 1

Pulmonary Function Testing

Baseline assessment must include:

• Forced vital capacity (FVC)
• Diffusing capacity for carbon monoxide (DLCO)
• Total lung capacity (TLC)
• 6-minute walk test (6MWT) with oxygen saturation monitoring 1

Lung Biopsy

Video-assisted surgical lung biopsy (SLB) is indicated when HRCT shows only possible UIP pattern and no contraindications exist. 1 Transbronchial lung cryobiopsy is an acceptable alternative in centers with appropriate expertise. 3

The decision to perform biopsy requires multidisciplinary discussion weighing:

• Operative risk based on age, comorbidities, and disease severity
• Potential to change diagnosis and management
• Patient preference 1

Do not perform biopsy if:

• HRCT shows typical UIP pattern (diagnosis already established)
• Prohibitive surgical risk
• Patient declines procedure 1

Multidisciplinary Discussion

All cases must be reviewed in multidisciplinary discussion involving pulmonologists, radiologists, and pathologists experienced in interstitial lung diseases. 1 Complex cases should be referred to expert centers. 1

Prognostic Assessment

At diagnosis, assess prognosis using:

• Severity of dyspnea
• FVC and DLCO values (DLCO <35-40% predicted indicates poor prognosis)
• Oxygen saturation at end of 6MWT (<88% indicates poor prognosis)
• Extent of honeycombing on HRCT
• Signs of pulmonary hypertension on echocardiography
• GAP score (gender, age, physiology) for 1-, 2-, and 3-year survival estimates 1

Management

Pharmacologic Treatment

For mild-to-moderate IPF (FVC ≥50% predicted and DLCO ≥35% predicted), initiate pirfenidone. 1 Treatment requires:

• Initiation by physician experienced in IPF management
• Regular monitoring of liver enzymes (monthly for first 6 months, then every 3 months)
• Smoking cessation (smoking increases pirfenidone metabolism)
• Avoidance of UV exposure
• Avoidance of concomitant omeprazole 1

For progressive pulmonary fibrosis in non-IPF interstitial lung diseases, use nintedanib. 3

Treatments NOT Recommended

Do not use the following therapies:

• Corticosteroids (except for acute exacerbations)
• Triple therapy with prednisone, azathioprine, and N-acetylcysteine
• Oral anticoagulants (warfarin increased mortality)
• Colchicine, cyclosporine A, interferon-γ-1b, etanercept
• Bosentan, macitentan, or ambrisentan (ambrisentan is contraindicated) 1

Supportive Care

Implement the following:

• Annual influenza and pneumococcal vaccination 1
• Long-term oxygen therapy for severe hypoxaemia at rest 1
• Ambulatory oxygen for oxygen saturation <88% during exercise 1
• Respiratory rehabilitation program for exercise limitation 1
• Low-dose oral corticosteroids (≤10 mg prednisone daily) for incapacitating cough unresponsive to codeine 1
• Low-dose morphine derivatives for severe dyspnea without hypercapnia 1

Lung Transplantation

Consider lung transplantation in all patients <65 years with severe or worsening disease. 1 Provide information early in disease course and arrange early assessment at transplant center. Specific criteria:

• DLCO <39% predicted
• FVC decrease >10% over 6 months 1

Monitoring and Follow-up

Patients require clinical visits and pulmonary function tests (FVC and DLCO) every 3-6 months. 1

Disease progression is indicated by:

• Progressive increase in dyspnea
• FVC decrease ≥10% (absolute or relative)
• DLCO decrease ≥15% (absolute or relative)
• Worsening fibrosis on HRCT
• Acute exacerbation 1

Perform HRCT when:

• Acute exacerbation suspected
• Unexplained clinical changes occur
• Lung cancer suspected
• Prior to lung transplantation 1

Acute Exacerbation Management

Diagnose acute exacerbation when:

• Recent worsening of dyspnea (<30 days)
• New lung opacities on imaging
• Other causes excluded (infection, pulmonary embolism, heart failure) 1

Treatment: High-dose corticosteroids; intravenous cyclophosphamide may be considered. 1

Important Caveats

• Lung cancer risk is increased 7-fold in IPF patients—maintain high index of suspicion and urge smoking cessation 1
• Comorbidities are common (cardiovascular disease, venous thromboembolism, diabetes, depression)—evaluate and manage appropriately 1
• Visits to specialized centers must occur at least annually, with interim visits possible at local facilities 1